Trial
NCT06692452
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Phase IIWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Eric Jacobsen, MD
Collaborators
Ipsen
Condition
Lymphoma
Intervention
Tazemetostat
Why stopped
Ipsen requested a temporary closure due to a safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-01